Skip to content

Study · Case report or series · n = 1 · 2025

3 results

Exposure to High-Dose Liraglutide in a Pregnant Woman With Obesity.

Abushanab D, Mohammed HR, Abdul Rouf PV, Thomas B, Al-Badriyeh D, Elkassem W, Al-Mohannadi H, Hanssens Y, Khan S, Mohammed S, Al Hail M

O&G open10 Apr 2025Cited by 5 (Europe PMC)

PMID41000293 (opens in a new tab)PMCIDPMC12456597 (opens in a new tab)DOI10.1097/og9.0000000000000077 (opens in a new tab)PepBankPUB-41000293
Read at sourcePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanCase report or seriesSafety outcome

    In a woman with obesity who took liraglutide 3 mg/d until 7 weeks of gestation, the neonate had low birth weight but was otherwise healthy.

    In plain wordsIn one woman who took liraglutide early in pregnancy, the baby had low birth weight but was otherwise healthy.

    Peptide
    Liraglutide
    Outcome
    Not applicableNeonatal birth weight and health after first-trimester exposure
    Study

    n = 1

    Outcome group
    Adverse events · Reproductive and sexual health
    Studied dose
    3 mg/d · subcutaneous · 8 monthsAs given in this study (human).

    Source sentences

    Summary
    the neonate had low birth weight but was otherwise healthy.
    1 context sentence
    Summary · context
    A 29-year-old woman, gravida 9 para 6, with obesity and no history of chronic diseases was admitted at 7 weeks of gestation after taking liraglutide 3 mg/d subcutaneously for weight loss for 8 months.
  2. 02HumanCase report or seriesSafety outcome

    In a child exposed to liraglutide 3 mg/d in the first 7 weeks of pregnancy, the neurodevelopmental assessment at 14 months postpartum was normal for age.

    In plain wordsIn one child whose mother took liraglutide early in pregnancy, development at 14 months was normal for age.

    Peptide
    Liraglutide
    Outcome
    No significant changeNeurodevelopmental assessment at 14 months
    Study

    n = 1

    Outcome group
    Adverse events · Nervous system and cognition
    Studied dose
    3 mg/d · subcutaneous · 8 monthsAs given in this study (human).

    Source sentences

    Summary
    normal neurodevelopmental assessment for age.
    1 context sentence
    Summary · context
    A 29-year-old woman, gravida 9 para 6, with obesity and no history of chronic diseases was admitted at 7 weeks of gestation after taking liraglutide 3 mg/d subcutaneously for weight loss for 8 months.
  3. 03HumanCase report or seriesSafety outcome

    In a child exposed to liraglutide 3 mg/d in the first 7 weeks of pregnancy, weight gain over 14 months postpartum was appropriate.

    In plain wordsIn one child whose mother took liraglutide early in pregnancy, weight gain over 14 months was appropriate.

    Peptide
    Liraglutide
    Outcome
    No significant changeChild weight gain to 14 months
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    3 mg/d · subcutaneous · 8 monthsAs given in this study (human).

    Source sentences

    Summary
    Follow-up during 14 months postpartum indicated appropriate childhood weight gain
    1 context sentence
    Summary · context
    A 29-year-old woman, gravida 9 para 6, with obesity and no history of chronic diseases was admitted at 7 weeks of gestation after taking liraglutide 3 mg/d subcutaneously for weight loss for 8 months.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.